Quviviq is manufactured by Idorsia Pharmaceuticals [1].
What is Quviviq used for?
Quviviq (daridorexant) is a medication prescribed for the treatment of insomnia in adults [1]. It works by blocking the activity of orexins, which are signaling molecules in the brain that promote wakefulness [2].
How does Quviviq work?
Quviviq is a dual orexin receptor antagonist. It inhibits the binding of orexin A and orexin B to both OX1R and OX2R receptors in the brain [1]. By blocking these receptors, Quviviq reduces the brain's wake-promoting signals, helping individuals fall asleep and stay asleep [2].
When did Quviviq become available?
Quviviq received FDA approval in January 2022 [1].
What are the potential side effects of Quviviq?
Common side effects of Quviviq can include sleep paralysis, unusual dreams, and headache [1]. It is important for patients to discuss any concerns about side effects with their healthcare provider.
Are there any risks associated with Quviviq?
Quviviq carries a risk of central nervous system depression and potential for complex sleep behaviors, such as sleepwalking or sleep-driving, while not fully awake [1]. Patients are advised not to drive or operate heavy machinery until they know how Quviviq affects them [1]. There is also a risk of hallucinations and temporary memory or concentration impairments [1].
What is the patent status of Quviviq?
Information on specific patent details for Quviviq can be found through resources like DrugPatentWatch.com [3]. Patents are crucial for determining market exclusivity periods for pharmaceutical products.
Who are Quviviq's competitors?
The market for insomnia treatments includes other medications that target different pathways or have different mechanisms of action. Competitors vary depending on the specific type of insomnia being treated and the patient's medical history.